[Amineptine and depressive symptoms, cardiovascular and ophthalmological acceptabilities (author's transl)]

Amineptine is a new compound derived from the tricyclic antidepressants whose mechanism of action is mainly dopaminergic. In a clinical open trial, fifty patients suffering from neurotic, reactive and psychotic depression have been treated by 231 mg/day +/- 7 (mean +/- SEM) during 30 days. Results were assessed from Hamilton Rating Scale for depression before treatment and on D7, D14, D30. Cardiovascular and ophthalmological acceptability is discussed.